ATE521893T1 - P66-shc als prädiktiver marker bei der krebsbehandlung - Google Patents

P66-shc als prädiktiver marker bei der krebsbehandlung

Info

Publication number
ATE521893T1
ATE521893T1 AT06837361T AT06837361T ATE521893T1 AT E521893 T1 ATE521893 T1 AT E521893T1 AT 06837361 T AT06837361 T AT 06837361T AT 06837361 T AT06837361 T AT 06837361T AT E521893 T1 ATE521893 T1 AT E521893T1
Authority
AT
Austria
Prior art keywords
shc
cancer treatment
predictive marker
individual
amount
Prior art date
Application number
AT06837361T
Other languages
English (en)
Inventor
A Frackelton
Original Assignee
Roger Williams Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger Williams Hospital filed Critical Roger Williams Hospital
Application granted granted Critical
Publication of ATE521893T1 publication Critical patent/ATE521893T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06837361T 2005-11-11 2006-11-10 P66-shc als prädiktiver marker bei der krebsbehandlung ATE521893T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73572905P 2005-11-11 2005-11-11
US84378806P 2006-09-12 2006-09-12
PCT/US2006/043852 WO2007058965A1 (en) 2005-11-11 2006-11-10 P66-shc as predictive marker in cancer treatment

Publications (1)

Publication Number Publication Date
ATE521893T1 true ATE521893T1 (de) 2011-09-15

Family

ID=37761924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837361T ATE521893T1 (de) 2005-11-11 2006-11-10 P66-shc als prädiktiver marker bei der krebsbehandlung

Country Status (7)

Country Link
US (1) US20080299590A1 (de)
EP (1) EP1946117B1 (de)
JP (1) JP2009516167A (de)
AT (1) ATE521893T1 (de)
AU (1) AU2006315651A1 (de)
CA (1) CA2627535A1 (de)
WO (1) WO2007058965A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910314B2 (en) 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
WO2015188056A1 (en) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001376A1 (en) * 1993-06-30 1995-01-12 Pharmacia S.P.A. Peptide inhibitors of mitogenesis and motogenesis
DE69408541T2 (de) * 1993-11-23 1998-08-06 Genentech Inc Kinaserezeptoraktivierungstest
US6673914B1 (en) * 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6492138B1 (en) * 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
JP5500750B2 (ja) * 2000-03-30 2014-05-21 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｒｎａ干渉のｒｎａ配列特異的メディエータ
WO2002028381A2 (en) * 2000-10-05 2002-04-11 Daley George Q Methods of inducing cancer cell death and tumor regression
CA2471777A1 (en) * 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20040209809A1 (en) * 2003-02-19 2004-10-21 Caroline Saucier Shc modulation and uses thereof
WO2007084156A1 (en) * 2006-01-20 2007-07-26 Catalyst Oncology, Lp Methods for prognosing the recurrence of gastrointestinal and other cancers using the shc proteins

Also Published As

Publication number Publication date
AU2006315651A1 (en) 2007-05-24
JP2009516167A (ja) 2009-04-16
US20080299590A1 (en) 2008-12-04
CA2627535A1 (en) 2007-05-24
EP1946117B1 (de) 2011-08-24
WO2007058965A9 (en) 2007-07-19
WO2007058965A1 (en) 2007-05-24
EP1946117A1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2008138578A3 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A3 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
TW200622950A (en) Methods of monitoring the concentration of an analyte
ATE533057T1 (de) Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
EP2637020A3 (de) Marker zur Vorhersage von Eierstockkrebs
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
DE602005007623D1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2007061922A3 (en) Methods to predict and prevent resistance to taxoid compounds
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
WO2005065365A3 (en) Systems and methods for aesthetic improvement
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
ATE521893T1 (de) P66-shc als prädiktiver marker bei der krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties